Featured Articles

  1. Why The Right Partner Matters In mAb Manufacturing 3/18/2026

    Early collaboration with an expert partner streamlines HME projects through optimized formulation, strong scale‑up, solid analytics, and adaptable technologies that boost performance.

  2. Streamline HME Projects With Early Partner Engagement 3/18/2026

    Global partner delivering end‑to‑end drug development, manufacturing, and packaging with deep expertise, advanced facilities, and support across key modalities.

  3. The Value Of Expertise In The Aseptic Fill Finish Of Biologics

    Aseptic fill finish manufacturing is critical for highly valuable biologic drug substances. With vast amounts of time and resources invested upstream, loss-resulting errors at such a late stage can be catastrophic.

  4. How Scale-Up Benefits A Clinical Program To Get Results

    A scalable manufacture promises increased process understanding and manufacturing flexibility to deliver a robust, reliable commercial product, and it helps with timely delivery to market.

  5. Data-Driven Approach Optimizes Robust, Scalable Lyophilization Process

    Selecting the right manufacturing partner with appropriate lyophilization expertise, experience, and analytical capabilities can speed drug development and expedite time to market for lyophilized drugs.

  6. Bilayer Tablet Manufacturing: An Overview

    Bilayer tablets offer a number of benefits for patient care; understanding the challenges that accompany their formulation is key to enabling their successful commercialization.

  7. CMO As Partners For ADC Process Development, Scale-Up, Optimization

    ADC programs can accelerate through clinical phases rapidly, making early preparation for commercial launch imperative. It's sensible to partner with a CMO with a strong biologics foundation.

  8. Minimizing API Supply Chain Risks

    Partnering with an API CMO can help you navigate challenges you may encounter, ensuring you are using the best quality practices and minimizing delays in getting those medicines to market.